Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTAM feasibility study of TDM-guided tamoxifen dosing in hormone-positive breast cancer
NL-OMON52690Active, not recruiting
- Sponsor
- Interne Oncologie
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Interne Oncologie. Primary endpoint: Adequate endoxifen target attainment at month 6 versus month 1. Started Feb 2018; status: active, not recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52690.